Journals / Viral Hepatitis Journal / 2017 / Cilt: 23 - Sayı: 3

Viral Hepatit Hastalarında Perkutan Karaciğer İğne Biyopsi Yöntemleri Güvenli ve Etkindir

Percutaneous Liver Needle Biopsy Methods Can Be Safe and Effective in Patients with Viral Hepatitis

Pages
65–70
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The use of a 16G biopsy needle was found to increase the probability of severe pain occurrence by about eight times.Conclusion: Severe pain was not affected by the biopsy method or patient-specific factors, and was a result of the size of the biopsy needle used and the characteristics of the practitioner

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aims of this study were to evaluate the biopsy methods used in terms of safety, and effectiveness as well as incidence, and severity of complications.Materials and Methods: This study was conducted as a prospective, observational study with the participation of five centers in Turkey.
📊
Key Findings & Data:Results: This research included 221 chronic hepatitis patients and 12 physicians.
💡
Conclusion & Impact:The use of a 16G biopsy needle was found to increase the probability of severe pain occurrence by about eight times.Conclusion: Severe pain was not affected by the biopsy method or patient-specific factors, and was a result of the size of the biopsy needle used and the characteristics of the practitioner
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The aims of this study were to evaluate the biopsy methods used in terms of safety, and effectiveness as well as incidence, and severity of complications.Materials and Methods: This study was conducted as a prospective, observational study with the participation of five centers in Turkey. Any patient complaints and/or complications were also recorded. The patients’ pain severity was determined by an established scoring method. Results: This research included 221 chronic hepatitis patients and 12 physicians. With regard to the biopsies, 71.9% were ultrasoundguided and 28.1% were blind biopsies. 71% of patients had complaints (mostly pain) and 19.9% developed complications; however, no mortality occurred. It was observed that patient’s complaints were significantly correlated with the physician’s age, level of biopsy experience, and number of biopsies performed yearly. It was determined that the biopsy method was not affective factor in terms of the development of severe pain after biopsy. The use of a 16G biopsy needle was found to increase the probability of severe pain occurrence by about eight times.Conclusion: Severe pain was not affected by the biopsy method or patient-specific factors, and was a result of the size of the biopsy needle used and the characteristics of the practitioner

Özet

Amaç: Bu çalışmada karaciğer biyopsi yöntemlerinin güvenilirliği, etkinliği ve komplikasyonların şiddetinin değerlendirilmesi amaçlanmıştır.Gereç ve Yöntemler: Bu araştırma Türkiye'de beş merkezin katılımıyla prospektif ve gözlemsel olarak gerçekleştirilmiştir. Hastaların şikayetleri ve/veya komplikasyonlar kaydedilmiştir. Hastaların ağrı şiddeti puanlama yöntemi ile belirlenmiştir. Bulgular: Çalışmaya 221 kronik viral hepatit hastası ve 12 hekim katılmıştır. Biyopsilerin %71,9'u ultrasonografi eşliğinde, %28,1 kör biyopsi yöntemi ile yapılmıştır. Hastaların %71'inde şikayet (çoğunluğu ağrı) ve %19,9'unda komplikasyon gelişmiştir. Ancak mortalite gözlenmemiştir. Biyopsiyi yapan hekimin yaş grubu, biyopsi deneyim süresi ve yıllık biyopsi sayısı ile şikayetlerin oluşması arasında anlamlı ilişki saptanmıştır. Biyopsi sonrası şiddetli ağrı gelişimi açısından biyopsi yönteminin etkili bir faktör olmadığı belirlenmiştir. Şiddetli ağrı varlığını 16G biyopsi iğnesi kullanmanın yaklaşık sekiz kat arttırdığı saptanmıştır.Sonuç: Şiddetli ağrının biyopsi yöntemi veya hastaya özgü faktörlerden etkilenmemekte, kullanılan biyopsi iğnesi ve uygulayıcının özelliklerinden kaynaklanmaktadır

🔖

Cite This Article

KARACAER, Z., KARADAĞ, F. Y., DURMUŞ, G., ÇİÇEK, H., PARLAK, E., ARI, A., TOSUN, S., DURMUS, Y., EREN, S., ADIBELLİ, Z. (2017). Viral Hepatit Hastalarında Perkutan Karaciğer İğne Biyopsi Yöntemleri Güvenli ve Etkindir. Viral Hepatitis Journal, Cilt: 23 - Sayı: 3, 65–70. https://ajindex.com/articles/332827

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Piekarska A. Principles of the Biopsy Procedure. In: Takahashi H (ed). Liver Biopsy In Tech; Available from: http://www.intechopen.com/ books/liver-biopsy/principles-of-the- biopsy-procedure. 2011; p. 25-32
  2. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. Gut. 1999;45(Suppl 4):iv1-iv11. Available from: http://gut.bmj. com/cgi/doi/10.1136/gut.45.2008.iv1 3. Al-Ghamdi ASG. Complications of liver biopsy. In: Takahashi H, (ed). Liver Biopsy. InTech Published; 2011. p. 363-370. Available from: http://www.intechopen.com/books/liver- biopsy/complications-of-liverbiopsy%0A 4. Machado NO. Complications of Liver Biopsy - Risk Factors, Management and Recommendations. In: Takahashi H(ed). Liver Biopsy. InTech Published; 2011. p. 393-404. Available from: http://www. intechopen.com/books/liver-biopsy/complications-of-liver-biopsy-riskfactors-management- and-recommendations 5. Thampanitchawong P, Piratvisuth T. Liver biopsy: complications and risk factors. World J Gastroenterol. 1999;5:301-304
  3. Eti Aslan F. Ağrı Değerlendirme Yöntemleri. C Ü Hemşirelik Yüksekokulu Derg. 2002;6:9-16
  4. Weigand K, Weigand K. Percutaneous liver biopsy: Percutaneous liver biopsy: retrospective study over 15 years comparing 287 inpatients with 428 outpatients. J Gastroenterol Hepatol. 2009;24:792-799
  5. Chi H, Hansen BE, Tang WY, Schouten JN, Sprengers D, Taimr P, Janssen HL, de Knegt RJ. Multiple biopsy passes and the risk of complications of percutaneous liver biopsy. Eur J Gastroenterol Hepatol. 2017;29:36-41
  6. Szymczak A, Simon K, Inglot M, Gladysz A. Safety and effectiveness of blind percutaneous liver biopsy: Analysis of 1412 procedures. Hepat Mon. 2012;12:32-37
  7. Terjung B, Lemnitzer I, Dumoulin FL, Effenberger W, Brackmann HH, Sauerbruch T, Spengler U. Bleeding complications after percutaneous liver biopsy: An analysis of risk factors. Digestion. 2003;67:138-145
  8. Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: A population-based study including 4275 biopsies. Liver Int. 2008;28:705-712
  9. Eisenberg E, Konopniki M, Veitsman E, Kramskay R, Gaitini D, Baruch Y. Prevalence and characteristics of pain induced by percutaneous liver biopsy. Anesth Analg. 2003;96:1392-1396
  10. Akay S, Karasu Z, Noyan A, Pala S, Musoğlu A, İlter T, Batur Y. Liver biopsy: Is the pain for real or is it only the fear of it? Dig Dis Sci. 2007;52:579-581
  11. Farrell RJ, Smiddy PF, Pilkington RM, Tobin A